^
    BRCA2 mutation
    Ovarian Cancer
    BGB-290
    Sensitive
    :
    A1
    BeiGene Press Release - 1d
    BRCA1 mutation
    Ovarian Cancer
    BGB-290
    Sensitive
    :
    A1
    BeiGene Press Release - 1d
    No biomarker
    Ovarian Cancer
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 1wk
    No biomarker
    Ovarian Cancer
    olaparib + bevacizumab
    Sensitive
    :
    A2
    NICE - 1wk
    HRD
    Ovarian Cancer
    olaparib + bevacizumab
    Sensitive
    :
    A1
    NICE - 1wk
    BRCA2 mutation
    Ovarian Cancer
    PARP inhibitor
    Sensitive
    :
    B
    JCO Glob Oncol - 3wk
    BRCA1 mutation
    Ovarian Cancer
    PARP inhibitor
    Sensitive
    :
    B
    JCO Glob Oncol - 3wk
    BRCA1 mutation
    Ovarian Cancer
    olaparib
    Sensitive
    :
    A1
    Lancet Oncol - 3wk
    BRCA2 mutation
    Ovarian Cancer
    olaparib
    Sensitive
    :
    A1
    Lancet Oncol - 3wk
    CCNE1 overexpression
    Ovarian Cancer
    AZD1775
    Sensitive
    :
    C3
    Clin Cancer Res - 3wk
    No biomarker
    Ovarian Cancer
    niraparib
    Sensitive
    :
    A1
    BRCA1 mutation
    Ovarian Cancer
    rucaparib
    Sensitive
    :
    A1
    BRCA2 mutation
    Ovarian Cancer
    rucaparib
    Sensitive
    :
    A1
    BRCA1 mutation
    Ovarian Cancer
    olaparib + bevacizumab
    Sensitive
    :
    A1
    BRCA2 mutation
    Ovarian Cancer
    olaparib + bevacizumab
    Sensitive
    :
    A1
    No biomarker
    Ovarian Cancer
    Aybintio (bevacizumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Ovarian Cancer
    Mvasi (bevacizumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Ovarian Cancer
    pegylated liposomal doxorubicin
    Sensitive
    :
    A1
    No biomarker
    Ovarian Cancer
    topotecan
    Sensitive
    :
    A1
    No biomarker
    Ovarian Cancer
    carboplatin + micellar paclitaxel
    Sensitive
    :
    A1
    No biomarker
    Ovarian Cancer
    bevacizumab
    Sensitive
    :
    A1
    BRCA1 mutation
    Ovarian Cancer
    niraparib
    Sensitive
    :
    A1
    BRCA2 mutation
    Ovarian Cancer
    niraparib
    Sensitive
    :
    A1
    No biomarker
    Ovarian Cancer
    Aybintio (bevacizumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Ovarian Cancer
    trabectedin
    Sensitive
    :
    A1
    HRD
    Ovarian Cancer
    niraparib
    Sensitive
    :
    A1
    No biomarker
    Ovarian Cancer
    olaparib
    Sensitive
    :
    A1
    No biomarker
    Ovarian Cancer
    rucaparib
    Sensitive
    :
    A1
    No biomarker
    Ovarian Cancer
    Zirabev (bevacizumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Ovarian Cancer
    Bevax (bevacizumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Ovarian Cancer
    docetaxel
    Sensitive
    :
    A2
    No biomarker
    Ovarian Cancer
    carboplatin + docetaxel
    Sensitive
    :
    A2
    No biomarker
    Ovarian Cancer
    ifosfamide
    Sensitive
    :
    A2
    No biomarker
    Ovarian Cancer
    5-fluorouracil
    Sensitive
    :
    A2
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES